Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, June 2001, p. 1794-1798, Vol. 45, No. 6
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.6.1794-1798.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Uptake, Transport, and Delivery of Antimicrobial
Agents by Human Polymorphonuclear Neutrophils
Gerald L.
Mandell* and
Elizabeth
Coleman
Division of Infectious Diseases, University
of Virginia Health System, Charlottesville, Virginia 22908-1341
Received 20 July 2000/Returned for modification 19 December
2000/Accepted 7 March 2001
 |
ABSTRACT |
Polymorphonuclear neutrophils (PMN) are attracted to sites of
infection. They have the potential to deliver antimicrobial agents to
these sites if the agents enter the cells and do not alter migration.
Penicillin G did not enter cells and was not transported by PMN. We
found that azithromycin, ciprofloxacin, levofloxacin, moxifloxacin, and
telithromycin were concentrated in PMN and transported toward a
chemoattractant. These antimicrobial agents were released from the PMN
and inhibited the growth of bacteria on test plates.
 |
INTRODUCTION |
Neutrophils and antimicrobial agents
have several potential interactions that may be synergistic for
combating infection. Antimicrobial agents make bacteria more
susceptible to killing by neutrophils even at subinhibitory
concentrations (1, 8, 14). Neutrophils target sites of
infection, concentrate at these sites, and thus may serve as an
antimicrobial agent delivery mechanism (4). In order for
neutrophils to function as an effective means of transporting
antimicrobial agents to sites of infection, several criteria must be
met: the agent should not interfere with neutrophil migration, the
agent should be concentrated in the neutrophil, and the agent should be
released in an active form at the site of infection. We examined
several agents, including newer quinolones and a ketolide, in an in
vitro system. Penicillin G was utilized because previous studies
(13, 15) showed that this antibiotic is not concentrated
in neutrophils.
 |
MATERIALS AND METHODS |
Determination of MICs.
The MICs of antimicrobial agents for
the organisms used in the assays were determined by the broth dilution
method (6).
Antimicrobial agents.
Azithromycin was provided by Pfizer
Pharmaceuticals, New York, N.Y.; ciprofloxacin was provided by Miles
Pharmaceuticals, West Haven, Conn.; levofloxacin was provided by
R. W. Johnson Pharmaceutical Research Institute, Spring House,
Pa.; telithromycin was supplied by Hoechst Marion Roussel, Romainville,
France; and moxifloxacin was supplied by Bayer Corporation, West Haven,
Conn. Penicillin G was obtained from Sigma Chemical Company, St. Louis, Mo. A stock solution of azithromycin was made by initially dissolving azithromycin in ethanol and then diluting this with Hanks balanced salt
solution (HBSS; BioWhittaker Inc., Walkersville, Md.). Stock solutions
of levofloxacin, ciprofloxacin, and moxifloxacin were made in sterile
water. A stock solution of telithromycin was made by resuspending
powder in 1% HCl and sterile water. The reported serum protein binding
of the antibiotics used was as follows: azithromycin, 7 to 50%
(depending on concentration); ciprofloxacin, 20 to 40%; levofloxacin,
24 to 38%; moxifloxacin, 30 to 45%; penicillin G, 60%; and
telithromycin, 70%.
Bacterial strains.
Streptococcus pyogenes ATCC
12344 (American Type Culture Collection, Manassas, Va.) was kept on
chocolate agar plates and subcultured every other day. For each
transport experiment, a 6-h culture of the organism in tryptic soy
broth (TSB; Difco Laboratories, Detroit, Mich.) grown at 37°C in 5%
CO2 was made. Overnight cultures of Micrococcus
luteus ATCC 9341, Staphylococcus aureus ATCC 27217, and
Escherichia coli ATCC 011B4 in TSB were used in bioassay
plates. Bacteria used for the assays were selected based on their
susceptibility to the antibiotic being studied.
Isolation of PMN.
Purified polymorphonuclear neutrophils
(PMN) were obtained from normal, heparinized (10 U of heparin
[Lymphomed Fujisawa USA Inc., Deerfield, Ill.] per ml) human venous
blood by a Ficoll-Hypaque separation procedure adapted from Ferrante
and Thong (3). Nine milliliters of fresh, heparinized
human blood was layered onto a gradient consisting of 1 ml of
Ficoll-Hypaque (ICN Biomedicals, Aurora, Ohio), 2 ml of One Step
Polymorphs (Accurate Chemicals and Scientific Corp., Westbury, N.Y.),
and 1 ml of neutrophil isolation medium (Cardinal Associates, Santa Fe,
N.M.). The blood with the separation medium was then centrifuged at
200 × g for 25 min to produce a layer of PMN. PMN were
removed and washed three times with HBSS (Whittaker M. A. Bioproducts, Walkersville, Md.) with 10 U of heparin per ml. Red blood
cells were lysed with 0.22% NaCl. Cells (95% PMN) were resuspended in
HBSS and counted using a hemocytometer.
Intracellular antimicrobial agent determination by bioassay.
A total of 5 × 106 PMN/ml were tumbled at 37°C for
1 h with either 0.1 µg of azithromycin/ml, 4 µg of
ciprofloxacin/ml, 6 µg of levofloxacin/ml, 4.5 µg of
moxifloxacin/ml, 10 µg of penicillin G/ml, or 0.1 µg of
telithromycin/ml. These concentrations are similar to published peak
concentrations in serum for humans after usual doses. After the
incubation period, the samples were centrifuged at 150 × g, the supernatants were decanted, and the pellets were blotted to
remove excess liquid. The remaining pellets were then transferred to a
1.5-ml Eppendorf tube containing 150 µl of silicone oil (General
Electric Company, Waterford, N.Y.) and microcentrifuged at 12,000 rpm
for 3 min. This brought the PMN pellet to the base of the tube and kept
the fluid supernatant on top separated by the oil. Supernatant and
silicone oil were removed by pipette. A sterile cotton swab was used to
wipe carefully around the PMN pellets to remove any remaining liquid.
The PMN pellets were freeze-thawed three times (using dry ice-acetone
slurry and a 37°C water bath) to lyse the cells. Then, 18 µl of
sterile water was added to each pellet, and the pellets were triturated
and placed into wells in seeded agar plates. Microscopic examination
indicated that all PMN were lysed.
Tryptic soy agar (TSA) was seeded with either M. luteus, E. coli, or S. aureus. An overnight culture of the
bacteria in TSB (1 ml per 50 ml of TSA for M. luteus or 1 ml
per 100 ml of TSA for E. coli or S. aureus) plus
1 ml of 1 M HEPES per 100 ml of TSA was mixed, and 30 ml of this
mixture was poured into each 150- by 15-mm petri dish (Becton Dickinson
Labware, Lincoln Park, N.J.) and allowed to solidify. A standard curve
relating the size of the zone of inhibition to the antimicrobial agent
concentration was prepared by placing 20 µl of four concentrations of
each antimicrobial agent in 4 mm-diameter wells and incubating these
known standards on the same plates as the samples.
M. luteus plates were used for azithromycin, penicillin G,
and telithromycin;
S. aureus plates were used for
moxifloxacin;
and
E. coli plates were used for ciprofloxacin
and levofloxacin.
The plates were incubated at 37°C in 5%
CO
2 overnight. The diameters
of the cleared zones were then
measured and plotted along a line
created from the standards to
determine the quantity of antimicrobial
agent released from the PMN.
The intracellular/extracellular (I/E)
volume ratios were calculated
utilizing a value for intracellular
water volume as previously
determined (
10).
Preparation of plates for transport of antimicrobial agents by
PMN.
Double-layer agar plates were made with a bottom layer of
chemotaxis agar and a top layer of TSA as previously described
(4). Wells of 3 mm in diameter were cut in the agar 4 mm
apart in a triplet pattern. Each plate contained one control sample
(PMN incubated without antimicrobial agent) in addition to samples of
PMN incubated with antibiotic.
PMN (5 × 10
6/ml) were tumbled with concentrations of
antimicrobial agents similar to peak levels in serum reported for
patients
after usual doses (2; F. Namour, D. H. Wessels, and M. Pascual,
Abstr. 37th IDSA Meet., abstr. 976, 1999): 0.1 µg of
azithromycin/ml,
4 µg of ciprofloxacin/ml, 6 µg of levofloxacin/ml,
4.5 µg of moxifloxacin/ml,
10 µg of penicillin G/ml, or no
antimicrobial agent at 37°C for
1 h. The PMN were washed twice by
centrifugation at 150 ×
g for
10 min, and the
supernatant was discarded to remove extracellular
antimicrobial agents.
A lower concentration of telithromycin (0.1
µg/ml) was used rather
than the usual serum telithromycin level
of 2.3 µg/ml, because the
zone of inhibition at this level was
too large to measure in our
system. Eight microliters of cell
suspension (approximately 2 × 10
5 PMN) was placed in each of the middle wells of a
triplet in the
agar plates. A 10
7 M concentration of
formyl-methionine-leucine-phenylalanine (fMLP)
was used as a
chemoattractant and placed in the outer wells. HBSS
was placed in the
inner well (Fig.
1). Plates were
incubated for
3 h at 37°C in 5% CO
2 to allow
migration of neutrophils. After
incubation, one set of plates was fixed
with 100% methanol, followed
by phosphate-buffered formalin
(
12). The agar was removed, and
plates were stained with
Giemsa stain. Neutrophil migration toward
the chemoattractant and
medium wells was measured under a microscope.

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 1.
Cartoon of plate used for antimicrobial agent transport
assay. The three small circles indicate 3-mm wells punched in agar
plates. PMNs were placed in the center well and allowed to migrate
toward the chemoattractant well (containing fMLP) or the medium well
(containing HBSS). The striped oval indicates the pattern of PMN
migration after 3 h. The inner oval indicates the area of
inhibition of bacterial growth. a, directed PMN migration; b,
nondirected PMN migration; c, inhibition of bacterial growth toward
chemoattractant well; d, inhibition of bacterial growth toward medium
well.
|
|
To determine the role of PMN migration in the transport of
antimicrobial agents, cytochalasin B (1.0 µg/10
6 PMN) was
used in some experiments to inhibit PMN movement (
7).
Cytochalasin B was dissolved in dimethyl sulfoxide (DMSO), and
some
experiments were performed with 1 µl of
DMSO.
Since a component of the inhibition of bacterial growth could be
related to antimicrobial agents diffusing out of the well
independently
of PMN movement, some experiments were performed
with two HBSS washes
of the PMN-containing well after the 3-h
chemotaxis
period.
Assay of release of antimicrobial agents from PMN.
After a
3-h incubation to allow the PMN to migrate, some plates were streaked
with a 6-h broth culture of S. pyogenes using a wire loop
and were incubated at 37°C in 5% CO2 overnight. The next
morning, the zones of inhibition of bacterial growth toward the
chemoattractant wells and the medium wells were measured under a
microscope (Fig. 1).
 |
RESULTS |
MICs.
The MICs of the antimicrobial agents used for S. pyogenes were as follows: azithromycin, 0.25 µg/ml;
ciprofloxacin, 0.312 µg/ml; levofloxacin, 0.625 µg/ml;
moxifloxacin, 0.16 µg/ml; penicillin G, 0.156 µg/ml; and
telithromycin, 0.0078 µg/ml. The MICs of the agents used for M. luteus were as follows: azithromycin, 0.125 µg/ml;
ciprofloxacin, 1.25 µg/ml; levofloxacin, 1.25 µg/ml; moxifloxacin, 0.312 µg/ml; penicillin G, 0.156 µg/ml; and telithromycin, 0.312 µg/ml. The MICs of the agents used for S. aureus were as
follows: azithromycin, 3.125 µg/ml; ciprofloxacin, 0.312 µg/ml;
levofloxacin, 0.312 µg/ml; moxifloxacin, 0.078 µg/ml; penicillin G,
0.625 µg/ml; and telithromycin, 0.125 µg/ml. The MICs of the agents
used for E. coli were as follows: ciprofloxacin, 0.0156 µg/ml; and levofloxacin, 0.0625 µg/ml.
PMN migration.
Results are expressed as mean ± standard
error of the mean (SEM) and were analyzed with the paired Student
t test. PMN migrated 2.92 ± 0.098 mm (n = 10) toward the chemoattractant well (directed migration) and
1.46 ± 0.098 mm (n = 10) toward the medium well (nondirected migration) (P < 0.05 [for the difference
between directed and nondirected migration]). None of the
antimicrobial agents studied affected migration distance. DMSO alone
reduced directed migration by 16.7% ± 2.3% (P < 0.001) and nondirected migration by 15.3% ± 3.2% (P < 0.001). DMSO plus cytochalasin B reduced directed migration by
65.1% ± 1.8% (P < 0.001) and nondirected migration
by 57.6% ± 3.1% (P < 0.001) (Fig. 1 and
2).

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 2.
PMN movement toward fMLP (directed migration) or medium
(nondirected migration). Hatched bars depict migration toward the HBSS
well; and solid bars depict migration toward the fMLP well. Pairs for
each condition were treated as follows (left to right): no additions,
1.0 µl of DMSO per well, and 1.12 µg of cytochalasin B plus 1.0 µl of DMSO per well. The antibiotics tested did not alter directed or
nondirected migration. Bars are means ± SEM. At least three
experiments were performed for each condition. Abbreviations: az,
azithromycin; cip, ciprofloxacin; lev, levofloxacin; mox, moxifloxacin;
pen, penicillin G; tel, telithromycin.
|
|
Uptake of antimicrobial agents.
Table
1 presents the intracellular and the
extracellular antimicrobial agent concentrations and the I/E ratios.
All antimicrobial agents studied except penicillin G were concentrated
in the neutrophils. Telithromycin and azithromycin achieved the highest
I/E ratios.
Transport of antimicrobial agents by PMN.
With the exception
of penicillin G, the antimicrobial agents tested showed a marked
increase in the zone of inhibition of bacterial growth in the direction
coinciding with the greatest PMN migration (Fig.
3). DMSO alone reduced inhibition of
bacterial growth toward fMLP by 16.6% ± 4.6% (P < 0.0001) and inhibition of growth toward HBSS by 12.5% ± 14.7%
(P < 0.001). DMSO plus cytochalasin B reduced
inhibition of growth toward fMLP by 44.5% ± 7.2% (P < 0.001) and toward HBSS by 14.4% ± 14.4% (P < 0.0001). Cytochalasin B, which inhibited directed PMN migration,
caused a marked reduction in inhibition of bacterial growth, indicating that PMN movement and antimicrobial agent transport accounted for the
increased zone of inhibition of bacterial growth. When PMN were studied
without antimicrobial agents, there was a small zone of inhibition of
bacterial growth that was greatest in the direction of greatest
migration. This was probably due to the antibacterial substances
present in the neutrophils (5). Telithromycin, a
ketolide antimicrobial agent that achieves high concentrations inside PMN (11), showed the most potent inhibition.
Although peak levels of telithromycin in serum after usual oral doses
are 2.3 µg/ml, we used lower concentrations in our studies because at
concentrations above 0.1 µg/ml, inhibition of bacterial growth extended into the medium and chemoattractant wells and could not be
measured.

View larger version (22K):
[in this window]
[in a new window]
|
FIG. 3.
Inhibition of bacterial growth by migrating PMN loaded
with antimicrobial agents. Hatched bars depict distance of inhibition
of bacterial growth toward the HBSS well; solid bars depict distance of
inhibition toward the fMLP well. Pairs for each condition were treated
as described in the legend to Fig. 2. The penicillin G pair had no
additions. Bars are means ± SEM. At least three experiments were
performed for each condition. Abbreviations: az, azithromycin; cip,
ciprofloxacin; lev, levofloxacin; mox, moxifloxacin; pen, penicillin G;
tel, telithromycin.
|
|
Washing of wells containing antibiotic-loaded PMN after 3 h (to
allow for chemotaxis) resulted in smaller zones of bacterial
inhibition
(Fig.
4). For example, washing of the PMN
loaded with
0.1 µg of telithromycin caused a 24% reduction
(
P = 0.02) of the
zone of inhibition in the direction
of fMLP. Inhibition of bacterial
growth seen with directed migration
was 1.99 times that of nondirected
migration without washing of the
wells, compared to a ratio of
2.21 after washing of the PMN. This
indicates that the PMN were
actually transporting and releasing the
antimicrobial agents.
Experiments performed with no PMN to determine
the efficacy of
washing the wells showed the following: for 1.25 µg
of telithromycin
per ml, washing of the well immediately resulted in a
zone of
bacterial inhibition that was 27% of that of the unwashed well
and washing after 3 h resulted in a zone of inhibition that was
46% of that of the unwashed well.

View larger version (16K):
[in this window]
[in a new window]
|
FIG. 4.
Effect of washing of wells after chemotaxis on
inhibition of bacterial growth by migrating PMN loaded with
antimicrobial agents. Results are similar to those shown in Fig. 3, but
the zones of inhibition are smaller. Hatched bars depict distance of
inhibition of bacterial growth toward HBSS; solid bars depict distance
of inhibition toward fMLP. Triplet pairs for each condition were
treated as described in the legend to Fig. 2. DMSO alone reduced
inhibition of bacterial growth toward fMLP by 8.5% ± 6.9% and did
not affect inhibition of growth toward HBSS. DMSO plus cytochalasin B
reduced inhibition of growth toward fMLP by 34.5% ± 11.0% and
inhibition of growth toward HBSS by 29.8% ± 8.2%. Bars are
means ± SEM. At least three experiments were performed for each
condition. Abbreviations: az, azithromycin; cip, ciprofloxacin; lev,
levofloxacin; mox, moxifloxacin; tel, telithromycin.
|
|
 |
DISCUSSION |
Antimicrobial agents and neutrophils have the potential to
interact in ways that enhance the therapy for infectious diseases. Bacteria that are exposed to antimicrobial agents are often more susceptible to ingestion and killing by phagocytes (1,
14). Microbes that can survive inside phagocytes are killed by
agents that penetrate the cell but not by agents that do not enter the phagocyte. Staphylococci inside neutrophils survive incubation with
beta-lactam antibiotics in concentrations that kill extracellular organisms, since these agents do not enter neutrophils. Rifampin enters
neutrophils and kills staphylococci residing in the phagocyte (9).
Intracellular antimicrobial agents may be in the cytoplasm or
concentrated in organelles (16). The rates of entry and
egress vary according to the agents and are not well studied for most antimicrobial agents.
In order for an antimicrobial agent to be effectively transported, it
must not interfere with the ability of the neutrophil to sense
chemoattractants and to move normally. We modeled antimicrobial agent
transport in an in vitro system and found that agents that are
concentrated by neutrophils were effectively carried along a
chemotactic gradient and inhibited the growth of a lawn of sentinel bacteria. Larger zones of inhibition were seen in the direction of the
chemoattractant and thus in the direction of the greatest migration
distance, indicating that neutrophils were actually transporting the
antimicrobial agents. Studies with cytochalasin B, a potent inhibitor
of neutrophil motility, showed that migrating neutrophils were
necessary for optimal effect.
Transport of antimicrobial agents by PMN is only part of a complex
series of events that includes entrance of the antibiotic into the PMN,
interaction of the agent with intracellular organelles, and efflux of
the active agent. The pharmacodynamics in vivo are also complex, since
in most instances, levels of drug in the blood vary widely and levels
in tissue may be very different from levels in blood. Thus, it is
possible that antimicrobial agents that appear to be transported poorly
diffuse out of the neutrophils rapidly during washing with
antimicrobial agent-free media. If this is the case, then levels of
antimicrobial agents in PMN should be expected to decrease markedly as
levels in serum fall and transport should be ineffective.
The in vitro system that we used showed those agents that were highly
concentrated and slowly released by PMN to be most effectively transported. This appears to be the case for azithromycin
(18) and telithromycin (17).
The antimicrobial agents studied included penicillin G, which does not
enter neutrophils and thus was not transported. The fluoroquinolones
ciprofloxacin, levofloxacin, and moxifloxacin were all concentrated in
the neutrophils and were effectively transported. Azithromycin and
telithromycin were highly concentrated in the neutrophils and were
transported very efficiently. We cannot explain why telithromycin
transport was not inhibited effectively by cytochalasin B plus DMSO. A
factor in the potency of the antimicrobial agents in inhibiting the
growth of the sentinel lawn of S. pyogenes is the in vitro
activity of the antimicrobial agent. The most active agent was
telithromycin, but penicillin G, despite its potency, was not
effectively transported.
Our results with ciprofloxacin differed from those reported in 1992 (4). At that time, it was noted that inhibition of bacterial growth was not significantly different in the direction of
the chemoattractant (P = 0.11). However, there was a
difference in the mean size of the zones of inhibition (1.40 versus
1.18 mm). Our present techniques have improved, resulting in increased chemotactic migration from 2.51 ± 0.16 mm in 1992 to 2.92 ± 0.098 mm at present. Nondirected migration was unchanged at 1.48 ± 0.12 mm in 1992 and 1.46 ± 0.098 mm at present. This change
was most likely due to a different method of neutrophil isolation and
lysis of red blood cells. The present system is also more sensitive in
detecting zones of bacterial inhibition. For example, in the present
study, 0.1 µg of azithromycin resulted in a 1.95 ± 0.337-mm zone of inhibition toward chemoattractant while in the 1992 study, 0.3 µg of azithromycin resulted in only a 1.0-mm zone of inhibition. Thus, transport of ciprofloxacin by PMN does occur.
The concept of antimicrobial agent transport by phagocytes is an
attractive one. Neutrophils home toward products of microbes and
molecules generated by the host cell's reactions to microbes and
concentrate at the site of infection. If neutrophils carry intracellular antimicrobial agents to these infection sites and release
the agents at these sites, this would be an effective way to enhance
the treatment of infections. Further study will be needed to determine
if this is clinically important.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from Aventis Pharmaceuticals,
Romainville, France; Ortho-McNeil Pharmaceutical, Raritan, N.J.; and
Bayer Corporation, West Haven, Conn.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Virginia Health System, P.O. Box 801341, Division of Infectious
Diseases, Charlottesville, VA 22908-1341. Phone: (804) 924-5942. Fax:
(804) 982-0002. E-mail: gm{at}virginia.edu.
 |
REFERENCES |
| 1.
|
Adinolfi, L., and P. F. Bonventre.
1988.
Enhanced phagocytosis, killing, and serum sensitivity of Escherichia coli and Staphylococcus aureus treated with sub-MICs of imipenem.
Antimicrob. Agents Chemother.
32:1012-1018[Abstract/Free Full Text].
|
| 2.
|
Amsden, G.
2000.
Tables of antimicrobial agent pharmacology, p. 551-601.
In
G. Mandell, J. Bennett, and R. Dolin (ed.), Tables of antimicrobial agent pharmacology, 5th ed. Churchill Livingstone, Philadelphia, Pa.
|
| 3.
|
Ferrante, A., and Y. H. Thong.
1980.
Optimal conditions for simultaneous purification of mononuclear and polymorphonuclear leucocytes from human blood by the Hypaque-Ficoll method.
J. Immunol.
36:109-117.
|
| 4.
|
Frank, M. O.,
G. W. Sullivan,
H. T. Carper, and G. L. Mandell.
1992.
In vitro demonstration of transport and delivery of antibiotics by polymorphonuclear leukocytes.
Antimicrob. Agents Chemother.
36:2584-2588[Abstract/Free Full Text].
|
| 5.
|
Ganz, T.
1997.
Antimicrobial peptides of leukocytes.
Curr. Opin. Hematol.
4:53-58[Medline].
|
| 6.
|
Jones, R. N.,
A. L. Barry,
T. L. Gavan, and J. A. Washington, II.
1985.
Susceptibility tests: microdilution and macrodilution broth Procedures, p. 972-977.
In
E. H. Lennette, A. Balows, W. J. Hausler, Jr., and H. J. Shadomy (ed.), Manual of clinical microbiology, 4th ed. American Society for Microbiology, Washington, D.C.
|
| 7.
|
Klebanoff, S., and R. Clark.
1978.
The neutrophil: function and clinical disorders;, p. 129-130.
Elsevier/North-Holland Biomedical Press, New York, N.Y.
|
| 8.
|
Lam, C.,
A. Georgopoulos,
G. Laber, and E. Schütze.
1984.
Therapeutic relevance of penicillin-induced hypersensitivity of staphylococcus aureus to killing by polymorphonuclear leukocytes.
Antimicrob. Agents Chemother.
26:149-154[Abstract/Free Full Text].
|
| 9.
|
Mandell, G., and T. Vest.
1982.
Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies.
J. Infect. Dis.
125:486-490.
|
| 10.
|
Mandell, G. L.
1973.
Interaction of intraleukocytic bacteria and antibiotics.
J. Clin. Investig.
52:1673-1679.
|
| 11.
|
Miossec-Bartoli, C.,
L. Pilatre,
P. Peyron,
E.-N. N'Diaye,
V. Collart-Dutilleul,
I. Maridonneau-Parini, and A. Diu-Hercend.
1999.
The new ketolide HMR3647 accumulates in the azurophil granules of human polymorphonuclear cells.
Antimicrob. Agents Chemother.
43:2457-2462[Abstract/Free Full Text].
|
| 12.
|
Nelson, R. D.,
R. T. McCormack, and V. D. Fiegel.
1978.
Chemotaxis of human leukocytes under agarose;, p. 25-42.
In
J. I. Gallin, and P. G. Quie (ed.), Leukocyte chemotaxis: methods, physiology, and clinical implications. Raven Press, New York, N.Y.
|
| 13.
|
Prokesch, R. C., and W. L. Hand.
1982.
Antibiotic entry into human polymorphonuclear leukocytes.
Antimicrob. Agents Chemother.
21:373-380[Abstract/Free Full Text].
|
| 14.
|
Root, R.,
R. Isturiz,
A. Molavi,
J. Metcalf, and H. Malech.
1981.
Interactions between antibiotics and human neutrophils in the killing of staphylococci.
J. Clin. Investig.
67:247-259.
|
| 15.
|
Schwab, J. C., and G. L. Mandell.
1989.
The importance of penetration of antimicrobial agents into cells.
Infect. Dis. Clin. N. Am.
3:461-467[Medline].
|
| 16.
|
Tulkens, P.
1991.
Intracellular distribution and activity of antibiotics.
Eur. J. Clin. Microbiol. Infect. Dis.
10:100-106[CrossRef][Medline].
|
| 17.
|
Vazifeh, D.,
A. Preira,
A. Bryskier, and M. Labro.
1998.
Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils.
Antimicrob. Agents Chemother.
42:1944-1951[Abstract/Free Full Text].
|
| 18.
|
Wildfeuer, A.,
H. Laufen, and T. Zimmermann.
1996.
Uptake of azithromycin by various cells and its intracellular activity under in Vivo conditions.
Antimicrob. Agents Chemother.
40:75-79[Abstract].
|
Antimicrobial Agents and Chemotherapy, June 2001, p. 1794-1798, Vol. 45, No. 6
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.6.1794-1798.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ulrich, M., Albers, C., Moller, J.-G., Dalhoff, A., Korfmann, G., Kunkele, F., Doring, G.
(2005). Moxifloxacin and Azithromycin but not Amoxicillin Protect Human Respiratory Epithelial Cells against Streptococcus pneumoniae In Vitro when Administered up to 6 Hours after Challenge. Antimicrob. Agents Chemother.
49: 5119-5122
[Abstract]
[Full Text]
-
Bosnar, M., Kelneric, Z., Munic, V., Erakovic, V., Parnham, M. J.
(2005). Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin. Antimicrob. Agents Chemother.
49: 2372-2377
[Abstract]
[Full Text]
-
Walters, J. D., Nakkula, R. J.
(2003). Ciprofloxacin Transport by Chemoattractant-Activated Polymorphonuclear Leukocytes: Regulation by Priming and Protein Kinase C. Antimicrob. Agents Chemother.
47: 3345-3348
[Abstract]
[Full Text]
-
Seral, C., Michot, J.-M., Chanteux, H., Mingeot-Leclercq, M.-P., Tulkens, P. M., Van Bambeke, F.
(2003). Influence of P-Glycoprotein Inhibitors on Accumulation of Macrolides in J774 Murine Macrophages. Antimicrob. Agents Chemother.
47: 1047-1051
[Abstract]
[Full Text]
-
Cacchillo, D. A., Walters, J. D.
(2002). Effect of Ciprofloxacin on Killing of Actinobacillus actinomycetemcomitans by Polymorphonuclear Leukocytes. Antimicrob. Agents Chemother.
46: 1980-1984
[Abstract]
[Full Text]